CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2004-09-20): Investigational drug fails to improve survival in melanoma metastasized to liver

Drug & Device Development

Investigational drug fails to improve survival in melanoma metastasized to liver

Last Updated: 2004-09-20 13:57:11 -0400 (Reuters Health)

PHILADELPHIA (Reuters) - Maxim Pharmaceuticals Inc. said a phase III trial to confirm the benefit of its drug Ceplene (histamine dihydrochloride) for patients with secondary liver cancer, failed to show an improvement in overall survival rates, the trial's primary endpoint.

The trial, undertaken to confirm the results of an earlier study, focused on patients with malignant melanoma that had metastasized to the liver. The confirmation study evaluated Ceplene in combination with interleukin-2 (IL-2). It has been approved in the U.S. for the treatment of advanced skin tumours.

In April, Maxim said it had received approval from the U.S. Food and Drug Administration to provide Ceplene to melanoma patients while investigation of the drug continued in the confirmation trial.

In May, the company reported positive results from a phase III trial investigating Ceplene plus IL-2 in the treatment of acute leukaemia (AML) in patients in complete remission. Maxim said it plans to seek regulatory approval in the U.S. and Europe to use Ceplene to treat AML patients.

The American-Swedish drugmaker will continue to evaluate the data from the current study and believes that Ceplene still holds promise for the treatment of certain cancers, it said in a statement.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2016 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.